BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
NCT ID: NCT00779064
Last Updated: 2014-12-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
36 participants
INTERVENTIONAL
2004-07-31
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Rivaroxaban (BAY59-7939)
10mg BID, Semi-sequential, dose escalation.
Arm 2
Rivaroxaban (BAY59-7939)
20mg BID, Semi-sequential, dose escalation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban (BAY59-7939)
10mg BID, Semi-sequential, dose escalation.
Rivaroxaban (BAY59-7939)
20mg BID, Semi-sequential, dose escalation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Japanese male or female
* Non- valvular atrial fibrillation documented by ECG
* Patients aged 60 years and older or with a risk of stroke
Exclusion Criteria
* Patients in whom anticoagulants are contraindicated
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fukuoka, Fukuoka, Japan
Fukuoka, Fukuoka, Japan
Kitakyushu, Fukuoka, Japan
Koga, Fukuoka, Japan
Kurume, Fukuoka, Japan
Kitahiroshima, Hokkaido, Japan
Amagasaki, Hyōgo, Japan
Kawachi-Nagano, Osaka, Japan
Osaka, Osaka, Japan
Osaka, Osaka, Japan
Osaka, Osaka, Japan
Suita, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11390
Identifier Type: -
Identifier Source: org_study_id